The increasing prevalence of uncommon fungal species and higher antifungal resistance has turned antifungal susceptibility testing into an important monitoring tool. In response, we evaluated the activity of isavuconazole against 522 clinical mold isolates collected worldwide in 2017-2018, including 436 Aspergillus spp. isolates and 86 non-Aspergillus molds. The MIC values using Clinical and Laboratory Standards Institute methods for isavuconazole versus Aspergillus ranged from 0.015 mg/L to >8 mg/L. Isavuconazole showed comparable activity to itraconazole, posaconazole, and voriconazole against A. fumigatus species complex. Most of the Aspergillus spp. isolates tested (>90%) were wild type to all azoles and echinocandins. Eleven isolates were non-wild type to isavuconazole and the other 3 azoles, and 10 of those isolates were from Europe. The azoles and echinocandins showed poor activity against Fusarium and Scedosporium spp. Isavuconazole exhibited excellent activity against most species of Aspergillus and was comparable to itraconazole, posaconazole, and voriconazole against the less common molds.

中文翻译：

---

2017-2018年SENTRY抗真菌监测计划中的伊沙康康唑对机会性丝状真菌病原体的体外活性。

罕见真菌种类的日益流行和更高的抗真菌耐药性已将抗真菌药敏试验变成重要的监测工具。作为回应，我们评估了伊沙康康唑对2017-2018年全球收集的522种临床霉菌的活性，其中包括436种曲霉属。分离物和86个非曲霉霉菌。使用临床和实验室标准协会方法测定的伊沙康唑与曲霉菌的MIC值范围为0.015 mg / L至> 8 mg / L。Isavuconazole对烟曲霉物种复合物的活性与Itraconazole，posaconazole和voriconazole相当。大多数曲霉属。测试的分离株（> 90％）是所有唑类和棘霉素类的野生型。十一株是非野生型的依沙康康唑，其余三株是唑类，其中有十株来自欧洲。吡咯和棘孢菌素对镰刀菌和Sedosporium spp的活性较弱。Isavuconazole对大多数曲霉菌均表现出优异的活性，并且对于较少见的霉菌，与Israconazole，posaconazole和voriconazole相当。